Development and Evaluation of a Topical Anti-Inflammatory Preparation Containing Dodonaea polyandra Extract

Authors

  • Bradley S Simpson Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia; Flinders Centre for Innovation in Cancer, Flinders University, GPO Box 2100, Adelaide, South Australia.
  • Xianling Luo 1 Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia; Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria, Australia.
  • Jiping Wang Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria, Australia.
  • Yunmei Song Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia.
  • David Claudie Chuulangun Aboriginal Corporation, PMB 30, Cairns Mail Centre, Cairns, Queensland, Australia.
  • Sanjay Garg Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia.
  • Nicholas Smith Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia.
  • Ross McKinnon Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia; Flinders Centre for Innovation in Cancer, Flinders University, GPO Box 2100, Adelaide, South Australia.
  • Susan Semple Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia.

DOI:

https://doi.org/10.18433/J38P57

Abstract

Purpose: We have previously reported that the Australian Northern Kaanju (Kuuku I’yu) medicinal plant Dodonaea polyandra has anti-inflammatory activity. This is attributed largely to the presence of clerodane diterpenoids contained within the leaf resin. We envisaged developing a topical preparation to treat indications relating to skin inflammation. However, it was unknown whether the resin could be incorporated into a suitable dosage form while retaining the therapeutic value demonstrated in previous work. Therefore, the following study was undertaken to assess parameters of safety and efficacy for a prototype formulation containing the leaf resin extracted from D. polyandra. Methods: Using the assessment criteria of optimum appearance, tactile feeling, spreadability and odour, 78 different formulations were developed. Formulation stability was assessed using a centrifugal test with preparations displaying phase separation further modified or re-formulated. A prototype formulation containing 5% w/w plant resin was selected and subjected to in vitro release studies. This was quantified through HPLC analysis using two major bioactive diterpenoids as reference. The prototype formulation was tested for efficacy in a TPA-induced acute murine skin inflammation model as well as a 3D human skin model for irritancy/toxicity (Epiderm™). Results: The prototype resin cream was a chartreuse-coloured homogenous semisolid preparation that was readily spreadable upon contact with skin with no sensation of tackiness, residual greasiness, or irritation. The optimized cream showed no phase separation after 30 min centrifugation at 825 g. In the TPA-induced inflammation model, the resin formulation significantly reduced ear thickness and interleukin-1 beta levels in mouse ear tissue. The 5% w/w resin cream formulation showed no irritancy in a 3D human skin model. Conclusions: Our results demonstrate that bioactive resin from D. polyandra can be formulated into a stable and non-irritant semi-solid dosage form and reduce parameters of acute skin inflammation in vivo.

 

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Downloads

Download data is not yet available.

Author Biographies

Bradley S Simpson, Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia; Flinders Centre for Innovation in Cancer, Flinders University, GPO Box 2100, Adelaide, South Australia.

Postdoctoral Fellow

Ross McKinnon, Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia; Flinders Centre for Innovation in Cancer, Flinders University, GPO Box 2100, Adelaide, South Australia.

Professor

Flinders Centre for Innovation in Cancer

Susan Semple, Sansom Institute for Health Research, University of South Australia, GPO, Adelaide, South Australia.

Senior Research Fellow, Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute for Health Research, University of South Australia

Downloads

Published

2015-10-24

How to Cite

Simpson, B. S., Luo, X., Wang, J., Song, Y., Claudie, D., Garg, S., Smith, N., McKinnon, R., & Semple, S. (2015). Development and Evaluation of a Topical Anti-Inflammatory Preparation Containing Dodonaea polyandra Extract. Journal of Pharmacy & Pharmaceutical Sciences, 18(4), 578-599. https://doi.org/10.18433/J38P57

Issue

Section

CLOSED. Special Issue - Chief Guest Editor: Basil D Roufogalis; Co-Guest Editors: Emanuel Strehler & Srinivas Nammi